Purine analogs in the treatment of chronic lymphocytic leukemia.
The purine analogs fludarabine (FAMP) and 2-chlorodeoxyadenosine (2-CDA) are highly active in chronic lymphocytic leukemia (CLL). In second-line therapy response rates are in the range of 30 to 60% and exceed 70% when applied to previously untreated patients. While FAMP in particular is thus well established for salvage treatment and can be considered as the present treatment of choice, more data are needed to define the role of purine analogs for first-line therapy.